@FSkoulidis
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
Associate Professor of Thoracic Medical Oncology @MDAndersonNews. Views are my own. #LungCancer
Joined May 2021
- Tweets13
- Following66
- Followers791
- Likes23
Incredibly proud of my daughter Isabella Skoulidis who summited M.Kilimanjaro to raise funds for children in Sudan. The climb has ended but the cause is more urgent than ever. #summitforSUDAN
Climbing for a Cause: Isabella’s Journey to Mount Kilimanjaro Summit for Sudan sapa-usa.org/summit-sudan/
Summit for Sudan | SAPA - Children in Sudan are facing a humanitarian crisis. SAPA,led by @YYElamin is providing life-saving aid. My 14-yo daughter is climbing M.Kilimanjaro to raise funds & awareness. Click the link below to support her journey.Thank you! sapa-usa.org/summit-for-suda…
Thrilled to share this exciting study @NatureMedicine. Largest integrative analysis of #sotorasib efficacy biomarkers to date. Grateful to all co- investigators and the Amgen team for their hard work and most of all to our patients. @MDAndersonNews #KRAS #NSCLC
Ferdinandos Skoulidis retweeted
From the November issue: Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-mutant NSCLC bit.ly/4einxFv
@_hanielaraujo, @XimoPechuan, Teng Zhou, @FSkoulidis, and colleagues @MDAndersonNews
Excited to share our new study @Nature. Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow @_hanielaraujo and @minhtruongdo. Thankful to our patients. @MDAndersonNews
Key points:
✅CTLA4 abrogates KEAP1/STK11-related PD-(L)1i resistance in NSCLC
✅Dual ICB engages CD4+ TH1/reprograms myeloid cells
✅Validation in POSEIDON. Results support 1st line dual ICB+chemo for STK11/KEAP1 MUT NSCLC
#STK11 #KEAP1 #CTLA4 #NSCLC nature.com/articles/s41586-0…
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM nejm.org/doi/full/10.1056/NE…
#ASCO2021 #KRAS #MDAndersonNews #Sotorasib
A big thank you to all patients and their families, clinical trial personnel and colleagues for making the practice changing CodeBreaK100 clinical trial possible. #ASCO2021 #KRAS #MDAndersonNews #Sotorasib
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM nejm.org/doi/full/10.1056/NE…
Ferdinandos Skoulidis retweeted
“The regulatory approval of sotorasib represents a major landmark for patients with KRAS G12C-mutated lung cancer,” says Dr. Ferdinandos Skoulidis of the now @FDA-approved targeted therapy drug that's helped trial participant Steve Castellaw. bit.ly/32REa9W #EndCancer
This seems like a good time to finally join twitter. On Friday 28th of May 2021 the FDA approved the first ever direct KRAS G12C inhibitor #sotorasib for patients with advanced KRAS p.G12C mutant lung cancer. After nearly 4 decades a truly historic milestone.